Trial NCT04992273

View at ClinicalTrials.gov 
Aliases: NCT05149300
Org. Study IDs: R10933-10987-COV-2121
Secondary IDs: 2021-004590-30

Last trial update was posted on 2023-03-06

MeSH Interventions

Casirivimab and imdevimab drug combination

MeSH Conditions

COVID-19

Other Conditions


Stopping Reasons

Emerging SARS-CoV-2 variants impacting susceptibility to study drug

Limitations And Caveats

The study was terminated early due to emerging SARS-CoV-2 variants impacting susceptibility to the study drug. The early termination was not due to safety findings.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID